Evidence map›Paper›PMID 34069550›Full record

ArticleCancers2021

A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with

Mohammed Khurshed, Remco J Molenaar, Myra E van Linde, Ron A Mathôt, Eduard A Struys, Tom van Wezel, Cornelis J F van Noorden, Heinz-Josef Klümpen, Judith V M G Bovée, Johanna W Wilmink

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Metformin and Cancer, an Ambiguanidous Relationship.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohammed KhurshedDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC location AMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0002-1611-1798
Remco J MolenaarDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC location AMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0001-5651-3997
Myra E van LindeDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC location AMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Ron A MathôtDepartment of Clinical Pharmacology, Cancer Center Amsterdam, Amsterdam UMC location AMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0001-8401-0879
Eduard A StruysDepartment of Clinical Chemistry, Cancer Center Amsterdam, Amsterdam UMC location VU, University Medical Center, 1081 HV Amsterdam, The Netherlands.
Tom van WezelDepartment of Pathology, Leiden University Medical Center, 2311 EZ Leiden, The Netherlands.ORCID 0000-0001-5773-7730
Cornelis J F van NoordenDepartment of Medical Biology, Cancer Center Amsterdam, Amsterdam UMC location AMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Heinz-Josef KlümpenDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC location AMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Judith V M G BovéeDepartment of Pathology, Leiden University Medical Center, 2311 EZ Leiden, The Netherlands.ORCID 0000-0003-1155-0481
Johanna W WilminkDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC location AMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Funding

Dutch Cancer Society 10460
6 · The paper itself

Abstract

backgroundMutations in isocitrate dehydrogenase 1 (

methodsPatients with

resultsSeventeen patients received study treatment for a median duration of 43 days (range: 7-74 days). Of twelve evaluable patients, 10 patients discontinued study medication because of progressive disease and two patients due to toxicity. None of the patients experienced a DLT. The MTD was determined to be 1500 mg of metformin two times a day and 200 mg of chloroquine once a day. A serum

conclusionTreatment of advanced

Indexed as

cancerchloroquinechondrosarcomaglioblastomaintrahepatic cholangiocarcinomaisocitrate dehydrogenasemetforminpharmacokinetics

Identifiers

PMID34069550
PMCPMC8161333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.